The U.S. Food and Drug Administration (FDA) has recorded the status of a HALOPERIDOL injectable product as discontinued. The submission, identified by application number ANDA070802, was filed by sponsor Smith & Nephew. The product is listed as an injectable dosage form (product number 001) and is not designated as a reference drug. Its active ingredient is HALOPERIDOL LACTATE, equivalent to 5 mg per milliliter of HALOPERIDOL base. The marketing status is noted as discontinued.
No further details were provided in the FDA notice.
規制動向2026年9月16日•3分で読めます
FDA Discontinues HALOPERIDOL Injectable (ANDA070802)
The FDA has marked the HALOPERIDOL injectable (product 001) as discontinued under application ANDA070802 submitted by Smith & Nephew.
Pharmacountryチームがまとめました · 出典: FDA.gov
トピック:
評価
(0)
(0)
(0)
(0)
(0)
評価を残す